机器人辅助纵隔肿瘤手术中国专家共识(2019版)

2020-01-01 中国医师协会 中国胸心血管外科临床杂志.2020,27(2):1-9.

纵隔是指左右两侧胸膜间隙及其内器官、结构和结缔组织的总称。纵隔肿瘤是纵隔内组织结构肿瘤性改变的统称,分为良性和恶性肿瘤。良性肿瘤如纵隔异位甲状腺、胸腺增生、纵隔囊肿、成熟性畸胎瘤、神经源性肿瘤等,恶性肿瘤如恶性胸腺瘤、胸腺癌、淋巴瘤、恶性神经源性肿瘤、生殖细胞肿瘤、纵隔内转移瘤等。纵隔空间狭小,结构复杂,组织来源多样,周围邻近大血管及心脏等重要脏器,目前治疗原则为仍以手术为主的综合治疗。传统开放性

中文标题:

机器人辅助纵隔肿瘤手术中国专家共识(2019版)

发布机构:

中国医师协会

发布日期:

2020-01-01

简要介绍:

纵隔是指左右两侧胸膜间隙及其内器官、结构和结缔组织的总称。纵隔肿瘤是纵隔内组织结构肿瘤性改变的统称,分为良性和恶性肿瘤。良性肿瘤如纵隔异位甲状腺、胸腺增生、纵隔囊肿、成熟性畸胎瘤、神经源性肿瘤等,恶性肿瘤如恶性胸腺瘤、胸腺癌、淋巴瘤、恶性神经源性肿瘤、生殖细胞肿瘤、纵隔内转移瘤等。纵隔空间狭小,结构复杂,组织来源多样,周围邻近大血管及心脏等重要脏器,目前治疗原则为仍以手术为主的综合治疗。传统开放性手术包括胸骨正中切口、胸骨部分劈开切口、蛤壳式切口、半蛤壳式切口、前外侧切口等,其胸骨或胸壁完整性受破坏,创伤大,出血多,暴露差,操作困难,手术时间长,术后疼痛明显,围手术期并发症较多。自 20 世纪以来,电视胸腔镜技术发展迅速,因其在手术切除率和临床效果与开放手术相同情况下,创伤更小,失血量更少,并发症发生率更低,目前在临床广泛推广使用。然而,纵隔内操作空间狭小,胸腔镜立体视觉感受差,胸腔镜器械较长,可能出现手部震颤,容易出现判断差错造成副损伤,且部分区域无法到达,切除难度大,对手术医师的技术要求较高。达芬奇机器人辅助手术因其能够提供更加精准、稳定、舒适的手术操作,能够更加微创、安全、彻底地完成肿瘤手术治疗,近年来逐渐在临床推广应用。我国 2006 年引进机器人手术系统并临床应用以来,国内一些医院成功开展了机器人辅助胸外科手术。随着机器人安装单位增加,机器人辅助纵隔肿瘤切除术者逐渐增多,稳定可传播的手术技术方法成为目前探索重点。

 

拓展指南:机器人相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=机器人辅助纵隔肿瘤手术中国专家共识(2019版))] GetToolGuiderByIdResponse(projectId=1, id=0f2061c0018a9012, title=机器人辅助纵隔肿瘤手术中国专家共识(2019版), enTitle=, guiderFrom=中国胸心血管外科临床杂志.2020,27(2):1-9., authorId=null, author=, summary=纵隔是指左右两侧胸膜间隙及其内器官、结构和结缔组织的总称。纵隔肿瘤是纵隔内组织结构肿瘤性改变的统称,分为良性和恶性肿瘤。良性肿瘤如纵隔异位甲状腺、胸腺增生、纵隔囊肿、成熟性畸胎瘤、神经源性肿瘤等,恶性肿瘤如恶性胸腺瘤、胸腺癌、淋巴瘤、恶性神经源性肿瘤、生殖细胞肿瘤、纵隔内转移瘤等。纵隔空间狭小,结构复杂,组织来源多样,周围邻近大血管及心脏等重要脏器,目前治疗原则为仍以手术为主的综合治疗。传统开放性, cover=, journalId=null, articlesId=null, associationId=1864, associationName=中国医师协会, associationIntro=, copyright=0, guiderPublishedTime=Wed Jan 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>纵隔是指左右两侧胸膜间隙及其内器官、结构和结缔组织的总称。纵隔肿瘤是纵隔内组织结构肿瘤性改变的统称,分为良性和恶性肿瘤。良性肿瘤如纵隔异位甲状腺、胸腺增生、纵隔囊肿、成熟性畸胎瘤、神经源性肿瘤等,恶性肿瘤如恶性胸腺瘤、胸腺癌、淋巴瘤、恶性神经源性肿瘤、生殖细胞肿瘤、纵隔内转移瘤等。纵隔空间狭小,结构复杂,组织来源多样,周围邻近大血管及心脏等重要脏器,目前治疗原则为仍以手术为主的综合治疗。传统开放性手术包括胸骨正中切口、胸骨部分劈开切口、蛤壳式切口、半蛤壳式切口、前外侧切口等,其胸骨或胸壁完整性受破坏,创伤大,出血多,暴露差,操作困难,手术时间长,术后疼痛明显,围手术期并发症较多。自 20 世纪以来,电视胸腔镜技术发展迅速,因其在手术切除率和临床效果与开放手术相同情况下,创伤更小,失血量更少,并发症发生率更低,目前在临床广泛推广使用。然而,纵隔内操作空间狭小,胸腔镜立体视觉感受差,胸腔镜器械较长,可能出现手部震颤,容易出现判断差错造成副损伤,且部分区域无法到达,切除难度大,对手术医师的技术要求较高。达芬奇机器人辅助手术因其能够提供更加精准、稳定、舒适的手术操作,能够更加微创、安全、彻底地完成肿瘤手术治疗,近年来逐渐在临床推广应用。我国 2006 年引进机器人手术系统并临床应用以来,国内一些医院成功开展了机器人辅助胸外科手术。随着机器人安装单位增加,机器人辅助纵隔肿瘤切除术者逐渐增多,稳定可传播的手术技术方法成为目前探索重点。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>机器人</FONT>相关指南:</STRONG><BR> <UL> <LI><A title=机器人辅助食管切除术中国临床专家建议(2019版) target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=0f2291c00180ae74">机器人辅助食管切除术中国临床专家建议(2019版)</A> <LI><A title="2019 国际共识声明:机器人胰腺手术" target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=669001c001e92784">2019 国际共识声明:机器人胰腺手术</A> <LI><A title=手术机器人辅助后寰枢椎内固定术指南-英文版 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=64eed1c001e376cf">手术机器人辅助后寰枢椎内固定术指南-英文版</A> <LI><A title="2018 国际共识声明:机器人肝切除术" target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=8cfa91c001e29a22">2018 国际共识声明:机器人肝切除术</A> <LI><A title="2018 EARCS欧洲共识:直肠癌标准化机器人全肠系膜切除术" target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=b77341c0016e18ff">2018 EARCS欧洲共识:直肠癌标准化机器人全肠系膜切除术</A> 更多信息请点击:<A target=_blank href="https://www.medsci.cn/guideline/list.do?q=%E6%9C%BA%E5%99%A8%E4%BA%BA">有关机器人更多指南</A></LI></UL>, tagList=[TagDto(tagId=98571, tagName=机器人辅助纵隔肿瘤手术)], categoryList=[CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5261, appHits=151, showAppHits=9, pcHits=2134, showPcHits=4030, likes=35, shares=7, comments=5, approvalStatus=1, publishedTime=Wed Jan 08 00:14:47 CST 2020, publishedTimeString=2020-01-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Jan 08 00:14:47 CST 2020, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 22:31:58 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=机器人辅助纵隔肿瘤手术中国专家共识(2019版))])
机器人辅助纵隔肿瘤手术中国专家共识(2019版)
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077089, encodeId=cb8e10e70890e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Dec 05 15:45:24 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056598, encodeId=f7611056598b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26505603467, createdName=ms1000001817409688, createdTime=Thu Sep 30 16:51:41 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925457, encodeId=e78c92545ec0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:59 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918322, encodeId=1da19183224a, content=喜欢这篇文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/7f19854a3e4a418082443e365cfbeeb7/5888366e86964474b89a587b7560afe3.jpg, createdBy=6c2a5454357, createdName=ms6000001708878858, createdTime=Wed Jan 20 11:36:09 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-12-05 1471d48dm72暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077089, encodeId=cb8e10e70890e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Dec 05 15:45:24 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056598, encodeId=f7611056598b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26505603467, createdName=ms1000001817409688, createdTime=Thu Sep 30 16:51:41 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925457, encodeId=e78c92545ec0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:59 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918322, encodeId=1da19183224a, content=喜欢这篇文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/7f19854a3e4a418082443e365cfbeeb7/5888366e86964474b89a587b7560afe3.jpg, createdBy=6c2a5454357, createdName=ms6000001708878858, createdTime=Wed Jan 20 11:36:09 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-09-30 ms1000001817409688

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077089, encodeId=cb8e10e70890e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Dec 05 15:45:24 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056598, encodeId=f7611056598b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26505603467, createdName=ms1000001817409688, createdTime=Thu Sep 30 16:51:41 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925457, encodeId=e78c92545ec0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:59 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918322, encodeId=1da19183224a, content=喜欢这篇文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/7f19854a3e4a418082443e365cfbeeb7/5888366e86964474b89a587b7560afe3.jpg, createdBy=6c2a5454357, createdName=ms6000001708878858, createdTime=Wed Jan 20 11:36:09 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-02-19 474576351

    不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1077089, encodeId=cb8e10e70890e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Dec 05 15:45:24 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056598, encodeId=f7611056598b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26505603467, createdName=ms1000001817409688, createdTime=Thu Sep 30 16:51:41 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925457, encodeId=e78c92545ec0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200801/19f50cb64c18415eaa3f0911d2873c50/7ab97989a34747339c05d63b82d6663d.jpg, createdBy=efbb4899905, createdName=474576351, createdTime=Fri Feb 19 13:47:59 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918322, encodeId=1da19183224a, content=喜欢这篇文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210120/7f19854a3e4a418082443e365cfbeeb7/5888366e86964474b89a587b7560afe3.jpg, createdBy=6c2a5454357, createdName=ms6000001708878858, createdTime=Wed Jan 20 11:36:09 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2021-01-20 ms6000001708878858

    喜欢这篇文章

    0